Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials
CONCLUSION: Evidence from the post-marketing safety data analysis identified a strong association between incretin mimetics and pancreatic events. Fewer events in RCTs may justify insignificant meta-analysis results.PMID:37986140 | DOI:10.1080/14740338.2023.2284992 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - November 21, 2023 Category: Drugs & Pharmacology Authors: Asif Muhammad Christy Thomas Vivekanandan Kalaiselvan Krishna Undela Source Type: research
SGLT ‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model
Sodium glucose co transporter-2 inhibitors (SGLT-2i); empagliflozin combined to metformin could enhance hormonal parameters, insulin resistance, and inflammatory biomarkers in rat model of PCOS-IR with modulating ovarian AMPK-SIRT1 pathway which may be the molecular basis for IR in PCOS and may potentially be a therapeutic target. AbstractPolycystic ovary syndrome (PCOS) is a common endocrine, reproductive, and metabolic disorder affecting females. The management of PCOS is challenging and current interventions are not enough to deal with all consequences of this syndrome. We explored the beneficial effect of combined sodi...
Source: Physiological Reports - November 21, 2023 Category: Physiology Authors: Manal Moustafa Mahmoud,
Laila Ahmed Rashed,
Somia Abdulatif Soliman,
Safaa Mostafa Sayed,
Omneya Kamel,
Samaa Samir Kamar,
Rania El Sayed Hussien Tags: ORIGINAL ARTICLE Source Type: research
Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis
Conclusion: Sotagliflozin displayed moderate CV benefits and acceptable safety. Sotagliflozin can be one of the recommended options for T2DM patients with HF or CV risk factors, which will be important for evidence-based use of sotagliflozin as well as decision-making of T2DM medication. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - November 17, 2023 Category: Drugs & Pharmacology Source Type: research
Do we stop SGLT2 inhibitor after UTI with septic shock?
A 90-year-old male with history of Coronary artery disease, Chronic obstructive pulmonary disease, Diabetes Mellitus, heart failure with reduced ejection fraction, urge incontinence, Gastro esophageal reflux disease, hypertension, Obstructive sleep apnea, stroke arrived at our Emergency Department for altered mental status of 1 day duration. He was started on empagliflozin 10 mg two months prior to presentation. His Blood pressure was 98/43 mmHg, pulse 93 bpm, temperature 37.9 °C, respirations 17 rpm, 92% on pulse oximetry on 2L nasal cannula. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - November 17, 2023 Category: General Medicine Authors: Ivan Arnaud-Borboa, Monish Sheth Tags: Clinical Communication to the Editor Source Type: research
Addition of adipose tissue-derived mesenchymal stem cells improves empagliflozin therapy for alleviating hyperglycemia--induced neuropathy
CONCLUSIONS: Combination of EMPA and ADMSC therapy was superior to either alone for improving outcomes of DN.PMID:37969202 | PMC:PMC10641353 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - November 16, 2023 Category: Research Authors: Hung-Sheng Lin Chien-Hui Yang Tsung-Cheng Yin Pei-Hsun Sung John Y Chiang Pei-Lin Shao Yi-Ling Chen Chi-Ruei Huang Hon-Kan Yip Kuan-Hung Chen Source Type: research
